CID-103 vs Sanritatug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
CID-103
Developed by CASI Pharmaceuticals, Inc.
NCT04758767 · Phase 1 · completed
All participants received CID-103 with no placebo or comparator arm and no blinding, so the design cannot show whether the antibody works better than another option. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Adverse events (approximately 18 months after study start): In 10 patients with previously treated relapsed and/or refractory multiple myeloma, CID-103 given as 30 mg/150 mg, 150 mg/300 mg, 150 mg/600 mg and 150 mg/900 mg doses was generally safe and well tolerated overall, but there was no beneficial impact on any patient's multiple myeloma. Nine of the 10 patients discontinued study drug due to progressive disease or lack of clinical benefit, and no further clinical trials with CID-103 are planned. (not_applicable)
Result source: NCT04758767
Sanritatug
Developed by Hangzhou Sumgen Biotech Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06508983 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | CID-103 | Sanritatug |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT06508983 |
| OS, median | —Not reported | —Trial running · NCT06508983 |
| ORR | —Not reported | —Trial running · NCT06508983 |
| VGPR or better | —Not reported | —Trial running · NCT06508983 |
| MRD negativity | —Not reported | —Trial running · NCT06508983 |
PFS, median
- CID-103
- —Not reported
- Sanritatug
- —Trial running · NCT06508983
OS, median
- CID-103
- —Not reported
- Sanritatug
- —Trial running · NCT06508983
ORR
- CID-103
- —Not reported
- Sanritatug
- —Trial running · NCT06508983
VGPR or better
- CID-103
- —Not reported
- Sanritatug
- —Trial running · NCT06508983
MRD negativity
- CID-103
- —Not reported
- Sanritatug
- —Trial running · NCT06508983
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
CID-103: no structured comparison results are available for Multiple Myeloma.
Sanritatug: no structured comparison results are available for Multiple Myeloma.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CID-103's landscape · Sanritatug's landscape